Micro RNAs (miRNAs) are small (~17-25 nt) regulatory molecules involved in regulation of gene expression. Impact of miRNA on transcriptome seems to be enormous and therefore, miRNAs have recently appeared in the centre of biomedically oriented research. Mature miRNAs are synthesized from precursor molecules with use of complex created by Drosha and DGCR8 (DiGeorge syndrome critical region gene 8) executing its function in the nucleus followed by Dicer cleavage in the cytoplasm (reviewed in Zhang et al. 2008; Deng et al. 2014) . miRNAs execute their function in the cytoplasm aft er loading into RISC (RNA-induced silencing complex) complex, containing Argonaute proteins that guides leading strand of miRNA duplex to complementary sequence of mRNA. miRNA usually inhibits expression of several target mRNAs.
Functions of miRNAs have been demonstrated in several physiological processes and they are believed to be implicated in many pathologies. It has been shown that miRNAs levels in the circulation frequently refl ect physiological status of the cell and/ or organ. Th anks to high miRNAs stability in plasma and serum, they show high potential to be employed as biomarkers (Reid et al. 2011) . Recent review provides a short overview of proved medically relevant miRNA/mRNA interactions. Knowledge about these interactions, in some cases, has been used in translational medicine, oriented on biomarker research and miRNA based therapeutics.
Proved miRNA-targets interactions important in human
Th ere are several eff ective means (Kiriakidou et al. 2004 ) for identifi cation of miRNAs targets. Th e search is based on knowledge about mammalian genomes available in public databases (e.g. TargetScan, PicTar, Miranda). Th anks to in silico tools availability for analysis of miRNA targets, a huge number of candidates for miRNA/mRNA interactions have emerged. Only a small proportion of them is fi rmly proved to be physiologically relevant. Many examples of miRNA/mRNA medically relevant interactions are provided in the next paragraph. Table 1 lists predominantly examples with strong experimental evidence. Th is part of miRNA research fi eld provides still a lot of space for experimental eff ort and it will be undoubtedly very fruitful in the near future.
Role of miRNA in development
lin-4 was the fi rst miRNA discovered and together with lin-7 belongs to the best-studied miRNAs. Th ey have been shown to act in a heterochronic pathway to regulate developmental timing in Caenorhabditis elegans (Lee et al. 1993; Wightman et al. 1993; Reinhart et al. 2000) . Loss of their function results in a retarded development (Lee et al. 1993) . lin-4 controls worm development at an earlier (Lee et al. 1993 ) and let-7 at a later stage (Reinhart et al. 2000) .
miRNAs can functioning as regulators of animal development at various tissues under diff erent developmental stages (Zhang et al. 2007a ). Some of the miRNAs, identifi ed in mouse (also conserved in human), seems to be highly tissue specifi c a thus may play a crucial role in the tissue diff erentiation and cell lineage decisions. miRNAs are essential for the normal development of various animal tissues (Lagos-Quintana et al. 2002) , including stem cells (Kanellopoulou et al. 2005) , embryo (Kanellopoulou et al. 2005 ), brain (Schratt et al. 2006) , heart (LagosQuintana et al. 2002) , limb (Harfe et al. 2005) , liver, and others (Lagos-Quintana et al. 2002) . miRNAs have been identifi ed to play a critical role in the fundamental brain developmental processes, e.g. neuronal diff erentiation. Neurodevelopmental and neural diff erentiation processes, occurring at various stages of life, can be compromised by disrupted miRNAs biogenesis (Szafranski et al. 2015) .
Specifi c role of miRNA in mammalian development is well supported. Several miRNAs have been reported to play a role in the regulation of stem cells and development of nervous system. miR-9 together with miR-124 and miR-125b appear to be associated with induction of human pluripotent stem cells differentiating into neurons (Roese-Koerner et al. 2013 ). Role of miR-124 in development of nervous system has been confi rmed by Makeyev et al. (2007) showing that miR-124 may participate in the diff erentiation of progenitor cells to mature neurons by regulating neuron-specifi c alternative splicing.
miRNAs are important in immune system development, function, and response. Th ey can facilitate the cell fate decision of immune cells, regulate the central elements of adaptive immune response, and aff ect the viral replication (Pedersen and David 2008) . It has been revealed that a number of miRNAs (e.g. miR-21, miR-29, miR-31, miR-155, miR-223, and many others) participate in the bone homeostasis including bone resorption, regulation of osteoclast diff erentiation, and osteoporosis . miR-150 can drive diff erentiation of megakaryocyteerythrocyte progenitors into megakaryocytes at the expense of erythroid cells in vitro and in vivo .
In spite of miRNA importance during development, only very few miRNAs are expressed and eff ective in early embryo (Th omson et al. 2006 ).
miRNA and cancer
Low abundance of miRNAs in the early embryonic cells resembles cell ongoing oncologic malformations, where miRNA synthesis is oft en down-regulated (Th omson et al. 2006; Mogilyansky and Rigoutsos 2013) . Th is is in accordance with the reduced Dicer expression, observed in fraction of patients with lung cancer and signifi cantly altered Dicer expression prognostic impact on their survival (Karube et al. 2005) .
Generally, miRNAs may function as oncogenes or tumor suppressor genes. Oncogene miRNAs or "oncomirs" usually promote tumor development by inhibiting the tumor suppressor genes or genes involved in control of cell diff erentiation and/or apoptosis. Th eir expression is increased in tumors. Tumor suppressor miRNAs are miRNAs that expression is decreased in cancerous cells. Th ey negatively inhibit oncogenes and/or genes that control the cell diff erentiation or apoptosis (Zhang et al. 2007b) . Numerous studies of malignancies, through over-expression or knockdown of some miRNAs, support the involvement of these miRNAs in tumorigenesis. Kumar et al. (2008) have shown that let-7 functionally inhibits non-small cell tumor development and its over-expression reduces tumor burden in a K-ras AGTR1 -angiotensin II receptor type 1; AR -androgen receptor; ATM -ATM serine/threonine kinase; CDK -cyclin-dependent kinase; CRY1 -cryptochrome 1; ESR1 -estrogen receptor 1; E2F3 -E2F transcription factor 3; IRS-1 -insulin like growth factor 1 receptor; LARS -large tumor suppressor 2; PDCD4 -programmed cell death 4; PER -period, PPP2R2A -protein phosphatase 2 regulatory subunit B, alpha; PTEN -phosphatase and tensin homolog; RAS -retrovirus associated sequence oncogene family; RASA1 -RAS p21 protein activator 1; RasGAP -Ras GTPase activating protein; RHOBTB1 -Rho-related BTB domain containing 1; RECK -reversion inducing cysteine rich protein with kazal motifs; RND3 -Rho family GTPase 3; SPRY -sprouty RTK signaling antagonist 2; THRAP -thyroid hormone receptor (TR) coregulator TR Associated protein 1; TIAM -T-cell lymphoma murine lung cancer model. Over-expression of miRlet-7a strongly suppresses proliferation, migration, and invasion of gastric cancer (GC) cells by downregulating the expression of PKM2 (M2 splice isoform of pyruvate kinase), which is a key regulator of aerobic glycolysis (Tang et al. 2016) . miR-214 directly targets E2F transcription factor 3 and thus suppresses the tumor proliferation in hepatocellular carcinoma (HCC) cells . Over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation in transgenic mice with non-small-cell lung cancer (NSCLC). miR-21 can drive tumorigenesis by inhibiting negative regulators of Ras/MEK/ERK pathway and apoptosis (Hatley et al. 2010 ). miR-21 seems to down-regulate the core mismatch repair (MMR) recognition protein complex, human mutS homolog 2, and 6 in human colon cancer cell lines. Cells overproducing miR-21 exhibit signifi cantly reduced 5-fl uorouracil (5-FU)-induced G2/M damage arrest and apoptosis that is characteristic of defects in the core MMR component (Valeri et al. 2010) . It seems that not only expression but also functions of some miRNAs are cancer specifi c. miR-31 was signifi cantly up-regulated in colorectal cancer (CRC) (Wang et al. 2009b ). In HCT-116 human colon cancer cells, suppression of miR-31 increases the sensitivity to 5-FU at an early stage and eff ects the cell migration and invasion (Wang et al. 2010b ). In serous ovarian cancer, miR-31 is down-regulated and its overexpression inhibits proliferation and induces apoptosis in many serous cancer cell lines with a dysfunctional p53 pathway. However, miR-31 has no effect in other lines with functional p53 (Creighton et al. 2010) . Th e study of Kim et al. (2015) have shown that miR-31 is aberrantly down-regulated in hepatocellular carcinoma and functions as a tumor suppressor by direct regulation of histone deacetylase 2 and cyclin-dependent kinase 2 (Kim et al. 2015) .
miRNA and cardiovascular system
Infl ammation plays an important role in host defense, however, is supposed to contribute to many acute and chronic diseases, such as ischemia/reperfusion damage and atherosclerosis (Silvestre et al. 2008) . It has been shown that some miRNAs can regulate vascular infl ammation. miR-126 is selectively expressed in endothelial cells, targets VCAM-1, suppresses its expression and thereby decreases leukocyte interactions with endothelial cells (Harris et al. 2008) . miRNAs can also be involved in mammalian angiogenesis. In HUVECs, 15 highly expressed miRNAs target angiogenic factors (Poliseno et al. 2006) and according to Kuehbacher et al. (2007) , miR-27b and let-7 can modulate angiogenesis.
Multiple miRNAs participate in the process of cardiac hypertrophy (Zhang 2008) . It has been shown that modulating aberrantly expressed miR-195 is suffi cient to modulate hypertrophy (van Rooij et al. 2006) . Decreased expression of miR-1 and miR-133 is associated with heart hypertrophy. On the other hand, miR-1 has been shown to be over-expressed in patients with coronary artery disease and silencing of miR-1 in infarcted rat hearts relieved arrhythmogenesis ). miR-21 has been implicated in the regulation neointima lesion formation (Ji et al. 2007 ).
miRNA and neural system
miRNAs are important in various aspects of neuronal structure, function, and long-term survival. miRNA dysfunction may promote neuronal degeneration and also subtle defi cits in the setting of neurodegenerative disease. Members of miR-29 family appear to have protective eff ects (Hebert et al. 2006; Kole et al. 2011; Szafranski et al. 2015) . On the other hand, other miRNAs may contribute to neurodegenerative diseases by promoting neurotoxic processes (Szafranski et al. 2015) . One of such miRNAs is miR-144, which positively correlates with human brain aging (Persengiev et al. 2011) .
Th ere might be a link between miRNAs and FMRP function (Corbin et al. 2009 ). FMRP is encoded by FMR1 gene. Transcriptional silencing of the FMR1 seems to account for fragile X syndrome, which is a common heritable cause of mental retardation (Ishizuka et al. 2002; Garber et al. 2008) .
Secretory miRNAs may be a part of the mediation of cell-to-cell communication. Results from Li et al. (2015) have shown that miRNAs can be present in synaptic vesicles (SVs) and suggested that SVs may regulate local protein synthesis by releasing transfer RNA fragments and miRNAs. Th e mechanism of horizontal transfer of miRNAs is not dependent only on vesicles but can also involve intracellular connections. Results of Zong et al. (2016) have indicated that miRNAs can pass through gap junction channels in a connexin-dependent manner to regulate gene expression in neighboring cells. Authors suggest that gap junctions can be important for intracellular genetic communication to synchronize and coordinate gene expression among cells. miRNAs appear to comprise a complex regulatory network which likely aff ects all levels of cellular func-tions. Besides above mentioned, miRNAs may play a role in many other processes.
Dynamics of miRNA in the circulation
Th e presence of miRNAs in circulation has led to the investigation of miRNAs as a novel diagnostic marker. However, mechanism of miRNAs secretion and their biological function has to be clarifi ed.
Th e fi rst evidence about the existence of miRNAs in the circulation has been provided by Chim et al. (2008) who identifi ed the placental miRNAs in maternal plasma of pregnant women. It has recently been accepted that miRNA can be analyzed in various body fl uids, including plasma, urine, saliva, and semen (Mitchell et al. 2008) . miRNA has been reported to be remarkably stable in human plasma and serum in spite of high endogenous RNase activity in the circulation (Mitchell et al. 2008) . Besides RNase activity, the serum miRNAs were resistant against treatment with harsh conditions, including digestion with RNase or DNase, low/high pH, extended storage or freeze-thaw cycles . Th ese qualities increase the possibility of detecting disease states from miRNA analysis in the circulation.
Origin and transport of circulating miRNA
Th e remarkable stability of miRNAs in plasma raises a question which mechanisms protect miRNAs from endogenous RNase activity. Th ree major mechanisms of miRNA secretions have been suggested (Figure 1 ):
1. passive leakage, as a result of cellular damage (injury, chronic infl ammation, apoptosis, necrosis, etc.); 2. active secretion through small membranebound vesicles (microvesicles, exosomes, and apoptotic bodies); 3. active secretion by association with macromolecular complexes: Argonaute proteins and high density lipoprotein (HDL) (Redis et al. 2012 ). An intravesicular transport of miRNAs can be carried in exosomes that are small 50-90 nm vesicles. miRNAs stored in circulating vesicles can be released by fusion of the vesicle with the cell membrane. Exosomes contain substantial amounts of RNA (mRNA and miRNAs) (Zampetaki et al. 2012) . Kosaka et al. (2010) have found that miRNAs are fi rst incorporated into the exosomal particles aft er which a surge of cellular ceramide stimulates the release of exosomes. Biosynthesis of ceramide is under regulation of neutral sphingomyelinase (nSMase). When HEK293 cells were treated with nSMase inhibitor GW4869, extracellular endogenous miR-16 and miR-146a were reduced in a dose-dependent manner but their cellular expression levels did not change. miRNAs packaged in exosomes can be delivered to recipient cells, where they act through the same mechanism and exert gene silencing as cellular miRNAs (Kosaka et al. 2010 ). Besides exosomes, miRNAs can be transported by other particles. Microparticles are larger than exosomes (>100 nm diameter) and similarly to exosomes, the miRNA export in microparticles is an actively regulated process. miRNAs are also present in the apoptotic bodies which arise as a response to apoptotic stimuli (Zampetaki et al. 2012) .
It remains elusive, how miRNAs are sorted into exosomes for their secretion. Diff erent composition of RNA between a donor cell and extracellular vesicles suggests that there are specifi c mechanisms, which enrich RNAs within secreted vesicles. Two types of extracellular vesicles, both described as exosomes, can diff er in their composition even if they are secreted by the same cell (Jose 2015 ). It appears that sorting of specifi c miRNA species to exosomes is an actively regulated process. Th e study conducted by Squadrito et al. (2014) has shown that miRNA sorting into exosomes is partly modulated by changes of miRNA target levels in the producer cells.
Secretory miRNAs have been hypothesized to participate in the mediation of cell-to-cell communication. However, it is not clear whether all extracellular miRNAs are associated with exosomes . Wang et al. (2010a) have proposed that signifi cant proportion of extracellular miRNAs can escape from the cell in exosome-independent manner. A variety of RNA-binding proteins, especially nucleophosmin 1 (NPM1), were released together with miRNAs into cell culture medium. NMP1 may play a role in the packaging and perhaps exporting the extracellular miRNAs (Wang et al. 2010a ). According to Turchinovich et al. (2011) , only a small minority of extracellular miRNAs can be associated with exosomes. However, in comparison with Wang et al. (2010a) , their data have suggested that the extracellular miRNAs are bound to Ago2. Th ey hypothesized that a large portion of the extracellular circulating miRNAs are by-products of dead or dying cells, persisting in the extracellular space due to the stability of the miRNA/Ago2 complex. However, the authors do not decline the possibility that some miRNAs could be associated with exosomes. Another study has confi rmed that vesicle-associated plasma miRNAs represent a minority, while the majority is pres-ent in protein complexes (Ago2) protecting miRNAs from plasma RNase (Arroyo et al. 2011 ). Ferreira et al. (2014 have demonstrated that AVM-BEC secretes RNA-binding protein Ago2, which is involved in part in the mediation of miR-18a delivery to brain endothelial cells. Moreover, miR-18a delivered by Ago2 is functionally active in both in vitro and in vivo conditions.
It has been proposed that miRNAs can also be carried in lipoprotein complexes. Vickers et al. (2011) have shown that high-density lipoprotein (HDL) can transport endogenous miRNAs and facilitate their delivery to recipient cells with functional targeting capabilities. Th e export of miR-223 to HDL has been found to be inhibited by nSMase2. It has been suggested that the export of specifi c miRNAs through the exosomal pathway and the HDL pathway could be distinct and possibly opposing mechanisms, although they are both likely regulated by nSMase2 activity and ceramide synthesis. miRNAs appear to be present also in low-density lipoprotein (LDL). It seems that HDL and LDL may share many of the most abundant miRNAs, but miRNA profi les diff er from each other (Vickers et al. 2011 ).
Import of miRNA into cells
Once being secreted into the extracellular space, exosomes are distributed through the body fl uids and reach target tissues and cells. It appears that the most Figure 1 . miRNAs in circulation may be transferred in several ways: they can be carried by vesicles (exosomes, microparticles, apoptotic bodies), protein complexes (NPM1, Ago) and lipoprotein complexes (HDL, LDL). Although numerous tissues can contribute to the circulating miRNA levels, miRNAs derived from blood cell represent a considerable part. HDL -high-density lipoprotein; LDL -low-density lipoprotein; Ago -Argonaute; NPM-1 -nucleophosmin 1; based on the data from Wang et al. (2010a) , Turchinovich et al. (2011 ), Pritchard et al. (2012 and Redis et al. (2012) . common way of extracellular vesicles (EV) uptake is endocytosis, including its subtypes such as macropinocytosis, phagocytosis, clathrin-mediated endocytosis, and caveolin-dependent endocytosis (Mulcahy et al. 2014) . Mulcahy et al. (2014) have reviewed several pathways, which may participate in the uptake of EV. Th ose mechanisms, among others, include protein interactions, which can facilitate endocytosis of EV. In a recent study, ovarian carcinoma cell line SKOV3 and its exosomes were treated with protease K. Aft er protease K administration, the exosome uptake was decreased, indicating that proteins that mediate the exosome internalization are present on the surface of cells and exosomes (Escrevente et al. 2011 ). Many classes of proteins (tetraspanins, integrins, immunoglobulins, proteoglycans, lectins, clathrin and caveolin) are likely to play a role in the interactions with membrane receptors and mediation of attachment and uptake of EV into cells. Th e EV can deliver their cargo also by direct fusion of its membrane with the cell plasma membrane (Mulcahy et al. 2014) .
It has also been observed that exosomes can be taken up via lipid raft domain. Disrupted exosomal lipid raft s resulted in an inhibition of internalization of exosomes. Annexins (mainly AnxA2 and AnxA6) were essential for exosome, traffi cking in BT-549 breast carcinoma cell line (Koumangoye et al. 2011) .
A question of EV uptake specifi city is not fully understood. Evidence is inconclusive in this respect. While some authors propose that EV are taken up by various cell types, others are suggesting that uptake of EV is a specifi c process, occurring only in the case of a correct combination of ligand and receptor between cell and vesicle (Mulcahy et al. 2014 ).
Exogenous miRNA
Th e possibility that miRNAs may regulate distant cells in one organism naturally raised a question whether even exogenous miRNAs obtained from other sources may have the same infl uence on gene expression. Some recent studies have suggested that exogenous miRNAs might have that capability. According to Zhang et al. (2012) , exogenous plant mature miR-168a can pass in food through gastrointestinal (GI) tract into the bloodstream and tissues and regulate the translation of its target gene in a fashion of mammalian functional miRNA. In another study, survival of an exogenous RNA was investigated in mice fed with plant RNA from Brassica oleacea. Exogenous plant miRNAs were detected in sera, feces, and several tissues. Th erefore, it has been proposed that they may survive in GI tract of mice and enter the peripheral blood and organs (Liang et al. 2014 ). In addition, miRNAs, derived from cow milk, seem to infl uence gene expression in human (Baier et al. 2014) . However, the function of extracellular miRNAs, obtained from nutrition, raises many questions. Title et al. (2015) have investigated intestinal miRNA uptake in newborn miRNA knockout mice fed with milk from wild-type foster mothers. Analysis of several tissues did not reveal detectable miRNA uptake from milk despite the fact that miRNAs are present in milk at high levels. Further investigation showed that milk miRNAs are degraded in intestinal fl uid. Authors have accepted a possibility that the small uptake level, which cannot be detected, is insuffi cient for the canonical miRNA function and thus milk miRNAs are more likely to represent a nutritional source (Title et al. 2015) . Dietary xenomiRNAs are a subject of an intense discussions (Witwer and Hirschi 2014) and further analysis are needed to elucidate their transfer and functional consequences.
How can be miRNA used in medicine?
Since the discovery of miRNAs in the blood and body fl uids, there is an intensive eff ort to reveal miR-NA potential to be used as biomarkers. Several examples implicate that miRNAs refl ect physiological state of the organism. Placenta specifi c miRNAs present in human plasma during pregnancy rapidly dropped after delivery. Authors of this study have demonstrated that placenta specifi c miRNAs are likely to be continuously released by exosomes from chorionic villi into maternal circulation and may target maternal tissues (Luo et al. 2009 ). Circulating plasma levels of miR-34a correspond to levels in the cochlea and auditory cortex during aging in mice. Th us, circulating miR-34a may refl ect ongoing cell loss in auditory organs during the age-related hearing loss (Pang et al. 2016) . Anyway, changes in miRNA levels are investigated much more in relation to disease with intention to improve existing diagnostic tools. Th e second cardinal interest is focused on the delivery of artifi cial miRNAs or miRNAs silencers to cure a disease.
miRNA-based biomarkers
Th e ideal biomarker should fulfi ll several criteria such as high specify to disease or organ, accessibility through non-invasive methods, sensitive to change in pathology process, and ability to early detect the disease before appearance of the clinical symptoms. Beside diagnostic markers, there is also a need for prognostic markers that could predict disease outcome and progression of patient survival (Etheridge et al. 2011) .
However, there is still not enough information available regarding the origin of miRNAs in the circulation. It is likely that a considerable portion of circulating miRNAs is derived from blood cells and organs. Recently, 58% of examined miRNAs that have been previously reported as circulating cancer biomarkers were found to be highly expressed in several types of blood cells. Th e majority of the biomarkers was also present in healthy plasma; however, at basal levels. Comparison of expression profi les of miRNAs in plasma to profi les of blood cells revealed that miRNA expression in plasma mirrors one of the blood cells. In addition, changes in blood cell counts and hemolysis may have signifi cant impact on plasma miRNA biomarker levels (up to 50-fold) (Pritchard et al. 2012 ).
Besides the above-mentioned complications, it is still a need to clarify whether miRNAs changes observed in the circulation are the result of cell death or cell secretion.
Circulating miRNAs in cancer. Identifi cation of robust diff erences in miRNA patterns, observed in diff erent cancer types and between cancer and healthy tissue, led to an idea that miRNA pattern could be used to diagnose specifi c type of oncologic malformations (Mogilyansky and Rigoutsos 2013) . A lot of attention has been paid to the potential of circulating miRNAs as biomarkers of cancer.
Expression of particular miRNA can be increased or decreased in cancer tissue (Lu et al. 2005) . Mogilyansky and Rigoutsos (2013) have observed downregulation of miRNA expression in the cancer tissue. On the other hand, some miRNAs have been shown to be up-regulated in cancer tissue, e.g. miRNAs from oncogenic cluster miR-17-92 (Mogilyansky and Rigoutsos 2013) .
Unfortunately, circulation does not refl ect miRNA expression tissue pattern perfectly. Besides, many circulating miRNAs, associated with cancer, may refl ect a secondary eff ect on blood cells (Pritchard et al. 2012) . Cancer-associated miRNAs in circulation may possibly originate in immunocytes. Tumor cells secrete a scale of miRNAs, modulating immune response in immunocytes that determines immunostimulatory or an immunotolerant tumor environment. Immunocytes may, vice versa, secrete miRNAs infl uencing tumor and thus promote or inhibit proliferation, invasion, and apoptosis. Th erefore, the cancer-associated miRNAs in circulation may have origin in the immune system and their dysregulation may represent a link between the cancer and immunity . Th ese fi ndings may point out on the importance of several possible sources of circulating miRNAs when assessing their potential as biomarkers.
According to Mitchell et al. (2008) , it is likely that many miRNAs expressed in tumor can aff ect the biological behavior and clinical phenotype of the tumor. Tumor cells secrete exosomes containing miRNAs that infl uence both the tumor and normal cells (Katsuda et al. 2014) . Most of the tumor-secreted exosomal miRNAs are oncogenic but some cell lines (for example metastatic gastric cancer cell lines) secret predominantly tumor suppressor let-7 miRNA, which could represent a way how the tumor cells may get rid of the tumor inhibiting miRNAs to maintain their oncogenesis and invasiveness (Ohshima et al. 2010) . Kosaka et al. (2010) have hypothesized that miRNAs down-regulated in cancer cells are compensated during the initial stage of the tumorigenesis by the surrounding cells, supplying exosomes containing the decreased miRNAs. However, once the surrounding cells cannot meet the demand, cancer cells enter an advanced stage.
Fluid-based biomarkers, currently used for cancer diagnostics, are mainly proteins (e.g. alpha-fetoprotein, chromogranin A, nuclear matrix protein 22, carbohydrate antigen 125), enzymes (e.g. prostate specifi c antigen), human chorionic gonadotropin, specifi c gene mutations, and others. In spite of the high number of recently used biomarkers, their clinical application is limited because of their low sensitivity and specifi city. Th erefore, the need for novel biomarkers is constantly growing .
Subgroup and meta-regression analysis of Zeng et al. (2015) have demonstrated that multiple miRNAs have higher predictive accuracy than a single one. According to their results, serum appears to a better matrix for miRNA assays than plasma in screening colorectal carcinoma (CRC). Identifi cation of the relationship between tissue miRNAs and circulating miRNAs would noticeably help to elucidate the origin of circulating miRNAs. Study from Mitchell et al. (2008) has shown that tumor-derived miRNAs can enter circulation and serve as a means for cancer detection. Th ey also have revealed a moderate correlation when compared plasma levels of miR-629 and miR-660 with tumor mass in mice. Toiyama et al. (2013) have observed a signifi cant correlation between miR-21 expression in tissues and serum of patients with CRC. High levels of miR-21 in tissues as well as serum were associated with a large tumor size, distant metastasis, and advanced TNM stage. Results have suggested that circulating miR-21 in serum may be produced by CRCs because of a signifi cant drop in serum miR-21 levels in postoperative serum (Toiyama et al. 2013) . miR-592 level in serum and CRC tissue was also up-regulated in CRC patients and signifi cantly decreased in postoperative serum compared to the preoperative serum level . Cheng et al. (2011) have observed that circulating levels of miR-141 are associated with metastatic CRC in stage IV and could serve as a prognosis marker to predict poor outcome and survival.
However, only miR-375 of fi ve investigated miRNAs (miR-150, miR-375, miR-125b, miR-206 and miR-126) showed correlation between tissue and plasma samples in CRC (Xu et al. 2014) . Pigati et al. (2010) have revealed that about 66% and not all of the released miRNAs are at an abundance closely refl ecting the cellular miRNA abundance of malignant mammary epithelial cells. Results of these authors have indicated that miRNAs are released partially selectively, which is important in considering diagnostic value of circulating miRNAs and assessing biological signifi cance of released miRNAs (Pigati et al. 2010) .
A number of miRNAs with decreased levels have also a high diagnostic potential. miR-601 and miR-760 showed reduced levels in plasma of patients with advanced adenoma (Wang et al. 2012a ). Other examples of down-regulated miRNAs in serum are miR-194 and miR-29b that inversely correlated with the cancer stage (Basati et al. 2015) . Reduced plasma levels of miR-24, miR-320a, and miR-423-3p have been observed in patients with CRC and benign lesions. Th eir levels increased aft er surgery of patients with clinical improvement .
A release of miRNA from cancer tissue has been studied with the use of prostate cancer xenograft implanted to immunocompromised mice. Results have shown that the levels of non-tumor specifi c miRNAs were not increased in mice plasma, while tumor specifi c miRNA were signifi cantly elevated. Authors supposed that miRNAs, originated from prostate cancer tissue, could be measured in the circulation. Th ey observed signifi cantly increased serum levels of miR-141 in patients with prostate cancer compared to healthy controls (Mitchell et al. 2008) . Another study has implicated elevated expression of miR-26a, as marker discriminating, between patients with prostate cancer and benign prostate hyperplasia (Mahn et al. 2011) . miRNA-375 and miRNA-141 have been reported to be up-regulated in cancer tissue compared to benign prostate tissue samples and were implicated as circulating markers of high-risk tumor (Brase et al. 2011) .
Both the tissue and serum levels of miR-128 were signifi cantly decreased in patients suff ering from prostate cancer and a close correlation between tissue and serum levels has been observed (Sun et al. 2015) .
In patients suff ering from the renal cell carcinoma (RCC), increased levels of 109 miRNAs were observed in the circulation compared to healthy controls, however, only 36 miRNAs were increased in cancer tissue as well plasma in RCC patients. Th is may indicate that only a small subset of circulating miRNAs has a tumor-specifi c origin. Increased miR-1233 values correlated with incidence of RCC, however, increase in miR-1233 levels was observed also in patients with angiomyolipoma or oncocytoma (Wulfk en et al. 2011) .
Measurements of miRNA in other body fl uids, e.g. saliva or urine, can be also used for cancer diagnosis. Concentrations of miR-126 and miR-182 have been reported to be increased in urine of patients suff ering from bladder cancer compared to control (Hanke et al. 2009 ). Up-regulation of miR-618 and down-regulations of miR-650 concentrations in urine has been suggested for early detection of hepatocellular carcinoma in high-risk hepatitis C virus infected patients (Abdalla and Haj-Ahmad 2012) . Approximately 50 miRNAs have been discovered in saliva of healthy probands in stable levels, protected from degradation and two of them (miR-200a and miR-125a) were present in signifi cantly lower levels in samples from patients with oral squamous cells carcinoma (Park et al. 2009 ).
Using circulating miRNA as biomarkers is complicated by the fact that their circulating levels are coming from diff erent sources and that miRNAs from circulation can refl ect every aspect of the human physiological state . It is important to note that some miRNAs show lack of disease specifi city. Since their up/down-regulated serum levels are present in various types of cancer, they may be useful as an universal rather than cancer specifi c markers (Hrustincova et al. 2015) . Typical example is miR-21 that has been reported to be signifi cantly changed in the circulation of patients with 5 solid tumors: breast, lung, colorectal, esophageal, and gastric cancer . Based on the recent knowledge about miRNA changes in circulation of cancer patients, diagnostic company Rosetta Genomics is currently off ering clinical test by using miRNA profi le that is able to identify the origin of metastatic cancer when the primary origin of metastasis is not clear (Hydbring and Badalian-Very 2013) . miRNAs and endocrine diseases. miRNAs have been evaluated as biomarkers of endocrine diseases as well. Th ey have been shown to be relevant in several organs, which are directly related to glucose metabolism (pancreatic islet, skeletal muscle, liver, brain and adipose tissue). Th ey can play a role in the insulin secretion and potentially in type 2 diabetes progression (Poy et al. 2007) .
Reduced levels of several miRNAs were found in plasma of patients suff ering from diabetes mellitus type 2. Th ese results have been confi rmed in animal model of hyperglycemia where high glucose concentration in circulation was associated with increased levels of miR-126 in endothelial apoptotic bodies (Zampetaki et al. 2010) . Another study has proposed a signifi cant decline in serum miR-23 as a potential biomarker for early detection of diabetes mellitus type 2 and pre-diabetes stages (Yang et al. 2014 ). In the serum of children with diabetes mellitus type 1, 12 up-regulated miRNAs have been identifi ed, whereas miR-25 was negatively associated with residual betacell function and positively associated with glycemic control (Nielsen et al. 2012) . In patients with metabolic syndrome levels of circulating miR-197, -23a, -509-5p, -130a, -195, -27a , and -320a were increased. Diseases contributing to metabolic syndrome were associated with specifi c miRNAs, e.g. miR-197, miR23a, and miR-509-5p were correlated with dyslipidemia, while miR-130a and miR-195as with hypertension (Karolina et al. 2012) . In the mouse model of obesity, a correlation between circulating level of miR-130b and BMI index has been observed. According to the above-mentioned authors, miR-130b may refl ect the degree of obesity and metabolic syndrome better than triacylglycerol levels in the plasma .
Other examples. In animal model, several miRNAs were more than 2-fold up-regulated or downregulated in the hippocampal tissue and circulation aft er ischemic strokes, brain hemorrhage or kainateinduced seizures. Th is implicates a possible use of miRNAs as biomarkers of brain injury or neurologic disease (Liu et al. 2010a) .
Circulating miRNAs have been suggested to be a promising biomarker for hepatocytes injury, caused by various factors (drugs, alcohol, some specifi c herbs) or infl ammation liver disease. Correlation of changed particular miRNA level with particular liver disease can provide further information about the mechanisms involved in liver pathology (Wang et al. 2009a; Su et al. 2012; Hornby et al. 2014) . Several serum miRNAs have been implicated to have a high potential for early detection of acute kidney injury (Aguado-Fraile et al. 2015) . Intensive research has also been focused on the identifi cation of miR-NA-based biomarkers for autoimmune disease, such as rheumatoid arthritis (miR-24 and miR-125-5p), lupus erythematosus (miR-126) or autoimmune thyroid diseases (Wang et al. 2012b; Murata et al. 2013; Yamada et al. 2014) .
By using an isoproterenol-induced cardiac injury in rats, a correlation between myocardial injury and plasma concentration of miR-208 was found. Moreover, miR-208 plasma levels showed a similar patter like cardiac troponin I that is accepted as a classic marker of myocardial injury (Ji et al. 2009 ). Concentration of the heart specifi c miR-499 in plasma also shows a signifi cant correlation with the level of blood troponin I in patients with acute infarction of myocardium (Adachi et al. 2010) . Plasma concentration of miR-519e-5p shows a decreased level aft er myocardium infarction but without association with ischemic stroke or pulmonary embolism. Th erefore, it has been suggested as a specifi c marker of myocardium infarction . Several other miRNAs, showing reduced levels in circulation aft er ischemic stroke, were implicated as potential biomarkers that can distinguish healthy control from patients (Long et al. 2013) .
Novel miRNA-dependent biomarkers may greatly improve the diagnosing or monitoring of early events in diseases and could help to start treatment earlier.
However, all the above-mentioned potential biomarkers need to be further evaluated before proceeding to actual clinical applications.
siRNA and miRNA based therapeutics
Th ere is a strong experimental eff ort focused on the development of artifi cial interfering RNAs for therapeutic use. Since longer double-stranded RNA (>30nt) shows a non-specifi c inducing of interferon immune response in mammalian cells, it was greatly appreciated that shorter ribonucleotide dsRNA can induce specifi c silencing in mammalian cells (Elbashir et al. 2001) .
Small interfering RNA (siRNA) has been employed in studies focused on RNA interference in mammalian cells sooner than miRNA. miRNA and siRNA share a number of similarities, however, not all of their features are identical. Th e most important diff erence resides in the target specifi city. Whereas, miRNAs can recognize multiple targets and show partial complementarity with them, siRNAs are highly specifi c and target only one mRNA. Th ey are currently used for silencing of specifi c genes that can be benefi cial in treating single gene disorders like hemophilia or hereditary amyloidosis.
Th erapeutic application of interfering RNAs is very promising. However, to be generally acceptable, it needs to overcome several problems. Before its application, delivery, specifi city of targeting, and stability of artifi cial interfering RNAs have to be improved. Chemical modifi cation of dsRNAs is oft en used to improve the stability and minimize the eff ect on immune system.
Th ere are several ways how to successfully deliver siRNA to organ, tissue or cell type without using virus-based delivery systems. Th e most intensively studied delivery methods are based on specifi c carries that can be -liposomes (vesicles having phospholipid bilayer), polymeric nanoparticles, polymeric micelles, dendrimers or metallic core nanoparticles (Gavrilov and Saltzman 2012) . Loading of siRNA into liposomes is a very promising strategy how to deliver the siRNA into the target organ. Th is system employs liposomes mediating fusion of siRNA cargo with the host cells. Moreover, neutral lipids are rather nontoxic and generally do not activate immune system response. Nanoparticles delivery systems off er high stability and controlled release of siRNA cargo via leaky vasculature in tumors. In case of using metallic nanoparticle, it is possible to tract distribution of nanoparticles via magnetic resonance imaging (Gavrilov and Saltzman 2012; Zuckerman and Davis 2015) .
Th e fi rst successful therapeutic delivery of siRNA has been performed by Koldehoff et al. (2007) . bcrabl siRNA delivered in liposomes administered to human oncological patient successfully inhibited over-expressed oncogene and resulted into increased apoptosis of cancer cells. However, this study was conducted only with single patient with chronic myeloid leukemia. Another clinical trial used nanoparticles to deliver siRNA to cells of solid cancer. Successful administration of nanoparticles and siRNA has been confi rmed by its intracellular localization in tumor tissue and absence in adjacent epidermis and decrease in target mRNA expression in tumor tissue (Davis et al. 2010) . Recently, the number of clinical studies, using RNA interference based therapy focused on treating of chronic myeloid leukemia, metastatic melanomas, and other solid tumors, is increasing.
Except of cancer treatment, clinical trials have been focused on the cure of HIV, hypercholesterolemia, glaucoma, and diabetic macular edema (Deng et al. 2014 ; http://clinicaltrials.gov/). siRNA based therapy was successfully used for preparation of nasal spray that directly target mRNA of the respiratory syncytial virus. Th is therapy had successful outcome with signifi cant antiviral activity (DeVincenzo et al. 2010) .
Th e therapeutic potential of miRNA is emerging as well. Researchers are using two approaches to develop miRNA-based therapeutics. Th e fi rst one is aimed on the development of miRNA silencers (antagomirs) that are specifi cally designed to inhibit endogenous production of miRNAs. Th is method was used in clinical trial focused on blocking liverexpressed miR-122. It has been found to be eff ective therapeutic approach in hepatitis C infection. Chemically modifi ed antisense oligonucleotides that sequester mature miR-122 administered to hepatocytes was able to block replication of the virus (Janssen et al. 2013) . Administration of the antisense oligonucleotides, designed to inhibit of miR-208a, showed that systemic silencing of miR-208a, a miRNA previously described as responsible for stress dependent cardiac remodeling and hypertrophy, prevents pathologic cardiac remodeling and diastolic dysfunction. Th ese eff ects have been observed only in the relation to cardiac stress response and not normal cardiac development (van Rooij et al. 2007) .
Another approach using miRNA replacement therapy, known as miRNA mimics, can restore reduced miRNA level and resume lost physiological function. Using of miRNA mimics is oft en suggested as an effi cient way for cancer therapy, because of the down-regulated miRNAs in tumors that are frequently functioning as tumor-suppressors. let-7 has previously been reported to target oncogene K-ras that is frequently mutated in several types of solid tumors. Th erapeutic delivery of let-7 seems to be effective in robust inhibition of tumor growth. Phase I study, focused on anti-cancer therapeutics employing miR-34 mimics, is ongoing. miR-34 is a well-known tumor suppressor that is engaged in p53 pathway and the anti-cancer eff ects mediated by miR-34 were observed in several solid tumors (liver, spleen, and kidney). Th is clinical trial is now recruiting new patients with liver carcinoma (Daige et al. 2014; Zuckerman and Davis 2015) . Another miRNA replacement based therapeutic is miR-16 mimics that is indicated in malignant pleural mesothelioma and non-small-cell lung cancer. Th is therapy uses nanoparticle drug delivery system and the study is expected to be fi nished in mid-2016 (Lam et al. 2015) .
Regenerative medicine also employs miRNA replacement therapy. It has been observed that nanoparticle delivery of proangiogenic miR-132 to endothelial cells before transplantation may enhance the transplantation process via sensitizing cells to the eff ects of endogenous growth factors (Devalliere et al. 2014) . miRNA cluster miR302-367 plays an important role in cardiomyocyte proliferation during development. Study based on the postnatal reactivation of miR-302-367 cluster have shown an increased cardiomyocytes proliferation and reduced scar formation aft er experimental myocardial infarction (Tian et al. 2015) . Th erapy with enhanced expression of miR-26a led to a better bone reparation due to increased angiogenesis and osteogenesis .
All above mentioned siRNA and miRNA focused studies have shown that this novel class of therapy can be safely dosed to human to alleviate symptoms or treat diseases. However, more preclinical and clinical human trials are needed to be conducted to reach the fi nal prove of this therapy for clinical practice.
Conclusions and perspectives
Signifi cance of miRNA focused experimental fi eld is growing and closely connected to ongoing research in human physiology and medicine. A summary of strong experimental evidence about the role of particular miRNAs in regulation of physiological processes and their involvement in pathologies is reviewed. Cells actively release miRNAs into the intracellular space and circulation and spectrum of excreted miRNAs refl ects cell state. miRNAs have been reported to be surprisingly stable in the circulation and therefore, useful for diagnostic purposes. Circulating miRNAs have been associated with physiological and pathological states, including various cancer types, cardiovascular diseases, sclerosis, liver injury or pregnancy. Although, several diagnoses have successfully been connected with increased or decreased levels of miRNA in the circulation, problem of a possible contamination by miRNA from blood cells and other sources in the organism is persisting. Many questions are still not answered. Mechanisms how intercellular signaling of miRNAs in the organism is executed are still misty, although, the fi rst experimental evidence, supporting extracellular signaling mediated by miRNA, is emerging. Delivery of artifi cial miRNAs is still struggling with insuffi cient stability of oligonucleotides and proper targeting of tissue, but progress in this fi eld is evident and synthetic miRNAs have already being tested in clinical trials.
